
Gland Pharma Ltd. share price
NSE: GLAND · Healthcare
₹3,385.90 +1.55%
Closing price data, updated 17 Nov 2026. 52-week range: -1.3% from high, +115.2% above low.
Price₹3,385.90
Market cap₹55,871 Cr
P/E45.2
P/B5.23
ROE10.5%
ROCE13.7%
Debt / equity0.03
Dividend yield0.00%
EPS₹74.90
Book value₹647.57
Operating margin18.8%
Dipscan score57 / 100
Share: WhatsAppX / TwitterTelegram
Gland Pharma Ltd. shareholding pattern
As of Sep 2026: Promoters 45.75%, FIIs 10.36%, DIIs 33.21%, Government 0.01%, Public 4.63%, Others 6.03%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 45.75% | 51.77% | 51.83% | 51.83% | 51.83% | 51.83% |
| FIIs | 10.36% | 8.74% | 7.30% | 7.58% | 7.91% | 7.39% |
| DIIs | 33.21% | 30.44% | 33.35% | 32.98% | 32.64% | 32.85% |
| Government | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 4.63% | 3.50% | 2.53% | 2.57% | 2.57% | 2.91% |
| Others | 6.03% | 5.55% | 4.98% | 5.04% | 5.06% | 5.02% |
| No. of Shareholders | 125,667 | 108,266 | 91,500 | 94,578 | 97,151 | 110,671 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| +1.55% | +6.83% | +10.93% | +14.10% | +78.37% | +80.00% |
Growth
| Sales growth, 3 years | +21.2% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +9.6% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 39.1%
Weaknesses
- Stock is trading at 5.23 times its book value
- Promoter holding has decreased over last quarter: -6.02%
- Company has a low return on equity of 9.29% over last 3 years.
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Gland Pharma Ltd.?
Gland Pharma Ltd. (GLAND) last closed at ₹3,385.90 (+1.55% on the day).
What is the market cap of Gland Pharma Ltd.?
About ₹55,871 Cr.
What is the P/E ratio of Gland Pharma Ltd.?
The price-to-earnings ratio is 45.2, and return on equity is 10.5%.
Figures are calculated from company results and exchange prices and are for information only.